Sign up online today & collaborate
or click here to find out more
Johnson & Johnson announced the publication of study data in the journal Science suggesting that its experimental prime-boost vaccine regimen could protect against global HIV-1 infection. "We are very encouraged by the results of this preclinical HIV vaccine study, and the findings lead to a clear path forward for evaluating this HIV vaccine candidate in humans," remarked lead author Dan Barouch.
The company indicated that the results "form the basis of vaccine regimens that are now being evaluated in an international Phase I/IIa clinical trial for safety and immunogenicity in healthy, HIV-uninfected volunteers." The study is currently registering 400 participants in the US and Rwanda to evaluate heterologous prime-boost regimens, with sites in South Africa, Uganda and Thailand expected to open soon. Barouch noted that the early-stage trial marks the first time a major drugmaker has sponsored clinical development of an HIV vaccine since Merck & Co.'s failed attempt in 2007.
For more click here
Source: First Word Pharma